ES2629317T3 - Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina - Google Patents

Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina Download PDF

Info

Publication number
ES2629317T3
ES2629317T3 ES14164565.5T ES14164565T ES2629317T3 ES 2629317 T3 ES2629317 T3 ES 2629317T3 ES 14164565 T ES14164565 T ES 14164565T ES 2629317 T3 ES2629317 T3 ES 2629317T3
Authority
ES
Spain
Prior art keywords
combination
treatment
administration
brain tumors
rapamycin derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES14164565.5T
Other languages
English (en)
Inventor
Heidi Lane
Terence O'reilly
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2629317(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2629317T3 publication Critical patent/ES2629317T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Abstract

40-O-(2-hidroxietil)-rapamicina para su uso como principio activo único en el tratamiento de tumores cerebrales sólidos distintos de cáncer linfático.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
5
10
15
20
25
30
35
40
45
50
55
hipertermia leve prolongada de todo el cuerpo y/o terapia de irradiación.
La administración de una combinación farmacéutica de la descripción no solo da como resultado un efecto beneficioso, por ejemplo, un efecto terapéutico sinérgico, por ejemplo con respecto a la ralentización, detención o inversión de la formación de neoplasias o una duración más larga de la respuesta frente al tumor, sino también efectos beneficiosos sorprendentes adicionales, por ejemplo menos efectos secundarios, una calidad de vida mejorada o una mortandad y morbilidad disminuidas, en comparación con una monoterapia que aplica solo uno de los principios farmacéuticamente activos usados en la combinación de la descripción, en particular en el tratamiento de un tumor que es refractario a otros agentes quimioterápicos conocidos como agentes anticancerígenos. En particular, se observa una absorción aumentada del coagente (b) en el tejido tumoral y las células tumorales, cuando se aplica en combinación con el primer agente (a).
Un beneficio adicional es que pueden usarse dosis más bajas de los principios activos de la combinación de la invención, por ejemplo, que las dosificaciones a menudo no sólo tienen que ser más pequeñas, sino que también se aplican con menor frecuencia, o pueden usarse para disminuir la incidencia de los efectos secundarios, mientras se controla el crecimiento de la formación de neoplasias. Esto es según los deseos y requerimientos de los pacientes que van a tratarse.
Los términos “coadministración” o “administración combinada” o similares tal como se usan en el presente documento se entiende que abarcan la administración de los agentes terapéuticos seleccionados a un solo paciente, y se pretende que incluyan regímenes de tratamiento en los que los agentes no se administran necesariamente por la misma vía de administración o al mismo tiempo.
Las composiciones farmacéuticas para la administración separada del primer agente a) y el coagente b) y para la administración en una combinación fija, es decir, una única composición galénica que comprende al menos dos componentes de combinación a) y b), según la invención pueden prepararse de manera conocida per se y son las adecuadas para la administración entérica, tal como oral o rectal, y parenteral a mamíferos (animales de sangre caliente), incluyendo seres humanos, que comprende una cantidad terapéuticamente eficaz de al menos un componente de combinación farmacológicamente activo solo, por ejemplo tal como se indica anteriormente, o en combinación con uno o más portadores o diluyentes farmacéuticamente aceptables, especialmente adecuados para la aplicación entérica o parenteral.
Las composiciones farmacéuticas adecuadas contienen, por ejemplo, de desde aproximadamente el 0,1% hasta aproximadamente el 99,9%, preferiblemente desde aproximadamente el 1% hasta aproximadamente el 60%, del/de los principio(s) activo(s). Las preparaciones farmacéuticas para la terapia de combinación para la administración entérica o parenteral son, por ejemplo, aquellas en formas de dosificación unitarias, tales como comprimidos recubiertos con azúcar, comprimidos, cápsulas o supositorios, o ampollas. Si no se indica lo contrario, estos se preparan de manera conocida per se, por ejemplo por medio de procesos de mezclado, granulación, recubrimiento con azúcar, disolución o liofilización convencionales. Se apreciará que el contenido unitario de un componente de combinación contenido en una dosis individual de cada forma de dosificación no necesita por sí mismo constituir una cantidad eficaz puesto que la cantidad eficaz necesaria puede alcanzarse mediante la administración de una pluralidad de unidades de dosificación.
Una cantidad terapéuticamente eficaz de cada uno de los componentes de combinación de la combinación dada a conocer en el presente documento puede administrarse simultánea o secuencialmente y en cualquier orden, y los componentes pueden administrarse por separado o como una combinación fija. Por ejemplo, el método de retraso del avance o tratamiento de una enfermedad maligna proliferativa según la descripción puede comprender (i) la administración del primer agente a) en forma de sal libre o farmacéuticamente aceptable y (ii) la administración de un coagente b) en forma de sal libre o farmacéuticamente aceptable, simultánea o secuencialmente en cualquier orden, en cantidades conjuntamente eficaces de manera terapéutica, preferiblemente en cantidades sinérgicamente eficaces, por ejemplo, en dosificaciones diarias o intermitentes correspondientes a las cantidades descritas en el presente documento. Los componentes de combinación individuales de la combinación dada a conocer en el presente documento pueden administrarse por separado en diferentes momentos durante el transcurso de la terapia
o de manera concurrente en formas de combinación divididas o únicas. Además, el término administración también abarca el uso de un profármaco de un componente de combinación que se convierte in vivo en el componente de la combinación como tal. Por tanto, la presente descripción debe entenderse como que abarca todos estos regímenes de tratamiento simultáneo o alternativo y el término “que administra” ha de interpretarse en consecuencia.
La dosificación eficaz de cada uno de los componentes de combinación empleados en la combinación dada a conocer en el presente documento puede variar según el compuesto o composición farmacéutica particular empleada, el modo de administración, el estado que se está tratando, la gravedad del estado que se está tratando. Por tanto, el régimen de dosificación de la combinación dada a conocer en el presente documento se selecciona según una variedad de factores incluyendo la vía de administración y la función renal y hepática del paciente. Un médico, clínico o veterinario experto puede determinar y recomendar fácilmente la cantidad eficaz de los principios activos individuales requeridos para prevenir, contrarrestar o detener el avance del estado. La precisión óptima para
8
imagen7

Claims (1)

  1. imagen1
ES14164565.5T 2001-02-19 2002-02-18 Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina Expired - Lifetime ES2629317T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0104072 2001-02-19
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds
GB0124957 2001-10-17

Publications (1)

Publication Number Publication Date
ES2629317T3 true ES2629317T3 (es) 2017-08-08

Family

ID=26245731

Family Applications (8)

Application Number Title Priority Date Filing Date
ES10174983.6T Expired - Lifetime ES2543383T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano
ES18155724T Expired - Lifetime ES2744377T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para tratar cáncer de páncreas
ES16186041T Expired - Lifetime ES2705016T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de cáncer de pulmón
ES10174985.1T Expired - Lifetime ES2600304T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores sólidos de riñón con un derivado de rapamicina
ES18155644T Expired - Lifetime ES2728739T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
ES14164259.5T Expired - Lifetime ES2640787T3 (es) 2001-02-19 2002-02-18 Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama
ES14164565.5T Expired - Lifetime ES2629317T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina
ES18155722T Expired - Lifetime ES2921798T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de tumores sólidos

Family Applications Before (6)

Application Number Title Priority Date Filing Date
ES10174983.6T Expired - Lifetime ES2543383T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano
ES18155724T Expired - Lifetime ES2744377T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para tratar cáncer de páncreas
ES16186041T Expired - Lifetime ES2705016T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de cáncer de pulmón
ES10174985.1T Expired - Lifetime ES2600304T3 (es) 2001-02-19 2002-02-18 Tratamiento de tumores sólidos de riñón con un derivado de rapamicina
ES18155644T Expired - Lifetime ES2728739T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
ES14164259.5T Expired - Lifetime ES2640787T3 (es) 2001-02-19 2002-02-18 Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18155722T Expired - Lifetime ES2921798T3 (es) 2001-02-19 2002-02-18 Derivado de rapamicina para el tratamiento de tumores sólidos

Country Status (27)

Country Link
US (10) US8410131B2 (es)
EP (11) EP2783686B1 (es)
JP (14) JP2004525899A (es)
KR (3) KR20070102762A (es)
CN (5) CN104274442A (es)
AU (1) AU2002250968C1 (es)
BR (1) BR0207378A (es)
CA (3) CA2438504C (es)
CY (11) CY1116616T1 (es)
CZ (5) CZ200591A3 (es)
DK (6) DK3143995T3 (es)
ES (8) ES2543383T3 (es)
HK (7) HK1146245A1 (es)
HU (1) HUP0303271A3 (es)
IL (13) IL157425A0 (es)
LT (9) LT2762140T (es)
LU (3) LU92880I2 (es)
MX (3) MX368013B (es)
NO (14) NO333105B1 (es)
NZ (1) NZ527692A (es)
PL (5) PL414997A1 (es)
PT (7) PT2269604T (es)
RU (8) RU2322981C2 (es)
SI (6) SI3143995T1 (es)
SK (5) SK288546B6 (es)
TW (2) TW200626151A (es)
WO (1) WO2002066019A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
PL414997A1 (pl) 2001-02-19 2016-02-29 Novartis Ag Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki
IL158800A0 (en) * 2001-06-01 2004-05-12 Wyeth Corp Antineoplastic combinations
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
BR0313048A (pt) * 2002-07-30 2005-06-14 Zentaris Gmbh Uso de alquilfosfocolinas em combinação com medicamentos antitumorais
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
CN100553634C (zh) * 2002-10-11 2009-10-28 达纳-法伯癌症研究公司 用于治疗多发性骨髓瘤的埃坡霉素衍生物
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR20120084333A (ko) * 2004-02-23 2012-07-27 노파르티스 포르슝스티프퉁 쯔바이크니덜라쑹 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 Ｍｔｏｒ 억제제와 세포독성제의 복합 치료에 대한 바이오마커로서의 ｐ53 야생형
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
AU2005225192B2 (en) * 2004-03-23 2008-10-09 Astrazeneca Ab Combination therapy
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
CN101137748B (zh) * 2005-03-07 2011-12-14 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
JP2009501765A (ja) * 2005-07-20 2009-01-22 ノバルティス アクチエンゲゼルシャフト ピリミジルアミノベンズアミドとｍＴＯＲキナーゼ阻害剤の組み合わせ
CN101360495B (zh) 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂
ES2481671T3 (es) * 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
HUE037890T2 (hu) 2006-02-02 2018-09-28 Novartis Ag Sclerosis tuberosa kezelése
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
CA2645488C (en) 2006-03-23 2014-09-02 Macusight, Inc. Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
RU2447891C2 (ru) * 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
PL2131821T3 (pl) * 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
EP2190409B9 (en) * 2007-08-16 2019-03-06 Biocompatibles UK Limited Delivery of drug combinations
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20120040896A1 (en) * 2008-04-11 2012-02-16 The Regents Of The University Of Colorado Compositions, methods and uses for modulation of brca 1
EP2318529B1 (en) * 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
EA036314B1 (ru) 2010-08-20 2020-10-26 Новартис Аг Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
EA036739B1 (ru) 2011-12-05 2020-12-15 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3)
DK3354293T3 (da) 2012-05-23 2020-02-17 Smith & Nephew Apparater til sårbehandling ved negativt tryk
US10667955B2 (en) 2012-08-01 2020-06-02 Smith & Nephew Plc Wound dressing and method of treatment
CN104661626B (zh) 2012-08-01 2018-04-06 史密夫及内修公开有限公司 伤口敷料
US10493184B2 (en) 2013-03-15 2019-12-03 Smith & Nephew Plc Wound dressing and method of treatment
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
PT3277842T (pt) * 2015-08-17 2019-09-05 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
MX2018011101A (es) * 2016-03-15 2018-11-22 Tyme Inc Composiciones farmaceuticas para el tratamiento del cancer.
WO2018100190A1 (en) 2016-12-02 2018-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
JP7217241B2 (ja) 2017-06-30 2023-02-02 ティージェイ スミス アンド ネフュー リミテッド 陰圧創傷治療装置
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
WO2019139921A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3098698A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
PE20212112A1 (es) 2018-05-01 2021-11-04 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
KR20230053539A (ko) 2021-10-14 2023-04-21 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994009019A1 (en) 1992-10-14 1994-04-28 Unichema Chemie B.V. Process for the preparation of alkylglycosides
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
NZ277498A (en) 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
AU2356195A (en) * 1994-04-14 1995-11-10 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
PT833828E (pt) * 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
AU3257297A (en) * 1996-06-11 1998-01-07 Novartis Ag Combination of a somatostatin analogue and a rapamycin
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
CN1235608A (zh) 1996-09-09 1999-11-17 美国家用产品公司 烷基化的雷帕霉素衍生物
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
WO1999049863A1 (fr) 1998-03-26 1999-10-07 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
JP3732525B2 (ja) * 1998-04-27 2006-01-05 アステラス製薬株式会社 医薬組成物
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
WO2001012633A1 (en) 1999-08-18 2001-02-22 American Home Products Corporation Water soluble sdz-rad esters
AU2292801A (en) 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
US6899731B2 (en) 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
JP2003519655A (ja) 2000-01-14 2003-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア リンパ増殖症候群の緩和および阻害のためのｏ−メチル化ラパマイシン誘導体
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
ATE278421T1 (de) * 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
ATE367836T1 (de) 2000-10-31 2007-08-15 Cook Inc Beschichtete, implantierbare medizinische geräte
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
WO2002056790A2 (en) * 2000-12-22 2002-07-25 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
PL414997A1 (pl) 2001-02-19 2016-02-29 Novartis Ag Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki
ES2312568T3 (es) 2001-04-06 2009-03-01 Wyeth Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo.
IL158800A0 (en) * 2001-06-01 2004-05-12 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
ES2481671T3 (es) 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
RU2609458C2 (ru) 2011-07-01 2017-02-01 Колопласт А/С Катетер с баллоном
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Also Published As

Publication number Publication date
BR0207378A (pt) 2004-06-15
RU2013119705A (ru) 2014-11-10
SK902019A3 (es) 2004-03-02
PT3143995T (pt) 2019-01-17
NO20150895L (no) 2003-10-17
SI3342411T1 (sl) 2019-10-30
EP2764865A2 (en) 2014-08-13
CY1119029T1 (el) 2018-01-10
EP2269603B1 (en) 2015-05-20
US20120214774A1 (en) 2012-08-23
RU2013143306A (ru) 2015-03-27
SK10382003A3 (sk) 2004-03-02
IL229157A0 (en) 2013-12-31
IL250676B (en) 2018-06-28
NO20131547L (no) 2003-10-17
HK1250019A1 (zh) 2018-11-23
KR20070102762A (ko) 2007-10-19
NO336208B1 (no) 2015-06-15
HK1146245A1 (zh) 2011-05-27
KR20050095906A (ko) 2005-10-04
CN1296043C (zh) 2007-01-24
CA2994779A1 (en) 2002-08-29
IL229160B (en) 2018-08-30
NO334646B1 (no) 2014-05-05
SI3351246T1 (sl) 2019-08-30
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
DK3342411T3 (da) 2019-09-02
CN104274442A (zh) 2015-01-14
PL415000A1 (pl) 2016-02-29
SK288524B6 (sk) 2018-01-04
TWI334350B (en) 2010-12-11
SI2269603T1 (sl) 2015-08-31
EP3143995B1 (en) 2018-12-05
CN104116738A (zh) 2014-10-29
CZ307637B6 (cs) 2019-01-23
EP2783686A8 (en) 2015-03-04
IL229158A (en) 2017-03-30
RU2006140514A (ru) 2008-05-27
SK288546B6 (sk) 2018-03-05
NO20161348A1 (no) 2016-08-24
PL363918A1 (en) 2004-11-29
DK2762140T3 (en) 2017-07-10
SK288630B6 (sk) 2019-01-08
LUC00122I1 (es) 2019-06-06
PT2762140T (pt) 2017-07-04
LTPA2020503I1 (lt) 2020-03-10
CZ2019248A3 (cs) 2004-01-14
JP2015145411A (ja) 2015-08-13
DK2269604T3 (en) 2016-11-14
JP2012184238A (ja) 2012-09-27
IL259724B (en) 2021-12-01
RU2018127821A (ru) 2020-01-30
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
TW200626151A (en) 2006-08-01
IL157425A (en) 2013-10-31
LT3342411T (lt) 2019-09-25
CZ307940B6 (cs) 2019-09-04
CY2019043I1 (el) 2020-05-29
NO340924B1 (no) 2017-07-17
CY2015044I1 (el) 2017-03-15
CY2019030I2 (el) 2020-05-29
PL409579A1 (pl) 2015-03-02
NO20190290A1 (no) 2003-10-17
JP6383814B2 (ja) 2018-08-29
PT3342411T (pt) 2019-09-19
CN104083365A (zh) 2014-10-08
LTC2269604I2 (lt) 2020-01-27
NO336581B1 (no) 2015-09-28
LU92880I2 (fr) 2016-11-17
RU2659725C2 (ru) 2018-07-03
JP6349475B2 (ja) 2018-06-27
EP2269604A1 (en) 2011-01-05
JP2007284454A (ja) 2007-11-01
WO2002066019A3 (en) 2002-10-24
JP2018100281A (ja) 2018-06-28
US20130059877A1 (en) 2013-03-07
LTPA2019511I1 (lt) 2019-06-25
CZ2018211A3 (es) 2004-01-14
LTPA2016035I1 (lt) 2016-12-27
LT2269604T (lt) 2016-11-10
RU2445093C2 (ru) 2012-03-20
EP2762140B1 (en) 2017-03-22
US20130296359A1 (en) 2013-11-07
SI3143995T1 (sl) 2019-02-28
NO333105B1 (no) 2013-03-04
CA2994779C (en) 2020-08-25
JP6310970B2 (ja) 2018-04-11
HK1198946A1 (en) 2015-06-19
CY2015044I2 (el) 2017-03-15
LT3143995T (lt) 2019-01-25
PT3351246T (pt) 2019-06-07
ES2705016T3 (es) 2019-03-21
IL220095A (en) 2017-05-29
CZ20032209A3 (cs) 2004-01-14
PL231418B1 (pl) 2019-02-28
JP6904640B2 (ja) 2021-07-21
NO20131546L (no) 2003-10-17
EP3345602B1 (en) 2022-04-06
CN1551767A (zh) 2004-12-01
IL250676A0 (en) 2017-03-30
CZ303611B6 (cs) 2013-01-09
CZ200591A3 (cs) 2019-01-23
NO20120451L (no) 2003-10-17
HK1250336B (zh) 2020-02-07
CA2860306A1 (en) 2002-08-29
JP2014193901A (ja) 2014-10-09
NO20131544L (no) 2003-10-17
CY1121983T1 (el) 2020-05-29
SK288545B6 (sk) 2018-03-05
EP2269604B1 (en) 2016-07-27
US8877771B2 (en) 2014-11-04
KR100695846B1 (ko) 2007-03-19
JP5775022B2 (ja) 2015-09-09
CY1121715T1 (el) 2020-05-29
EP3342411A1 (en) 2018-07-04
NO20150831A1 (no) 2015-06-24
IL220096A0 (en) 2012-07-31
RU2011138835A (ru) 2013-03-27
CY2016047I2 (el) 2017-04-05
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
ES2600304T3 (es) 2017-02-08
EP3406249A1 (en) 2018-11-28
ES2728739T3 (es) 2019-10-28
RU2322981C2 (ru) 2008-04-27
WO2002066019A2 (en) 2002-08-29
DK3351246T3 (da) 2019-06-03
MX368013B (es) 2019-09-13
JP5873128B2 (ja) 2016-03-01
RU2005105664A (ru) 2006-08-10
JP6333766B2 (ja) 2018-05-30
LT2762140T (lt) 2017-06-26
CZ309247B6 (cs) 2022-06-22
US8778962B2 (en) 2014-07-15
KR20040007451A (ko) 2004-01-24
JP2014208657A (ja) 2014-11-06
IL157425A0 (en) 2004-03-28
US20130244951A1 (en) 2013-09-19
JP5879391B2 (ja) 2016-03-08
US8436010B2 (en) 2013-05-07
LU93320I2 (fr) 2017-01-30
MX2019010879A (es) 2019-12-16
CA2860306C (en) 2018-04-17
ES2640787T3 (es) 2017-11-06
IL251270A0 (en) 2017-06-29
ES2543383T3 (es) 2015-08-18
IL202155A (en) 2013-04-30
ES2744377T3 (es) 2020-02-24
US20130253000A1 (en) 2013-09-26
RU2003127391A (ru) 2005-03-27
SK288834B6 (sk) 2021-03-10
HK1250018B (zh) 2020-04-17
US20120283285A1 (en) 2012-11-08
IL229159A0 (en) 2013-12-31
EP2762140A1 (en) 2014-08-06
NO336428B1 (no) 2015-08-17
AU2002250968B2 (en) 2006-01-12
CY2016047I1 (el) 2017-04-05
DK2269603T3 (en) 2015-08-24
ES2921798T3 (es) 2022-08-31
IL220095A0 (en) 2012-07-31
IL220096A (en) 2015-10-29
JP6349476B2 (ja) 2018-06-27
PT2269604T (pt) 2016-11-04
EP3342411B1 (en) 2019-08-21
KR100695846B9 (ko) 2021-09-30
EP3143995A1 (en) 2017-03-22
CA2438504A1 (en) 2002-08-29
EP3345602A1 (en) 2018-07-11
JP2018100282A (ja) 2018-06-28
NO2015010I1 (no) 2015-03-30
IL259724A (en) 2018-08-30
CY2019030I1 (el) 2020-05-29
HK1197723A1 (zh) 2015-02-13
LUC00122I2 (es) 2019-12-24
US20160303092A1 (en) 2016-10-20
US20140105895A1 (en) 2014-04-17
NO20130045L (no) 2003-10-17
NO20150413L (no) 2003-10-17
HUP0303271A3 (en) 2010-09-28
JP6349474B2 (ja) 2018-06-27
CY1121314T1 (el) 2020-05-29
NO335134B1 (no) 2014-09-22
EP1363627A2 (en) 2003-11-26
DK3143995T3 (en) 2019-01-28
SI2269604T1 (sl) 2016-11-30
NO343599B1 (no) 2019-04-08
IL202155A0 (en) 2010-06-16
JP2018100283A (ja) 2018-06-28
JP2018168188A (ja) 2018-11-01
SI2762140T1 (sl) 2017-07-31
EP2783686A1 (en) 2014-10-01
IL251270B (en) 2018-06-28
CZ2010473A3 (es) 2004-01-14
CY2020005I1 (el) 2020-05-29
PL414997A1 (pl) 2016-02-29
CA2438504C (en) 2016-02-16
CZ309178B6 (cs) 2022-04-20
US8410131B2 (en) 2013-04-02
IL229158A0 (en) 2013-12-31
MXPA03007418A (es) 2003-11-18
EP3351246B8 (en) 2019-09-18
JP2017081979A (ja) 2017-05-18
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
PT3345602T (pt) 2022-07-04
US20130287769A1 (en) 2013-10-31
JP2016222705A (ja) 2016-12-28
NO20131545L (no) 2003-10-17
AU2002250968C1 (en) 2018-01-04
LT3351246T (lt) 2019-07-10
CY1118316T1 (el) 2017-04-05
JP2004525899A (ja) 2004-08-26
NO336110B1 (no) 2015-05-18
EP2269603A1 (en) 2011-01-05
EP2764865A3 (en) 2014-10-01
RU2018121314A3 (es) 2021-10-06
NZ527692A (en) 2005-05-27
NO20033651L (no) 2003-10-17
US20040147541A1 (en) 2004-07-29
PL414996A1 (pl) 2016-02-29
NO20170803A1 (no) 2003-10-17
CN1679559A (zh) 2005-10-12
HK1146247A1 (en) 2011-05-27
JP2014177469A (ja) 2014-09-25
JP2020143134A (ja) 2020-09-10
CY1116616T1 (el) 2017-03-15
NO340553B1 (no) 2017-05-08
HUP0303271A2 (hu) 2004-01-28
IL229160A0 (en) 2013-12-31
IL229156A0 (en) 2013-12-31
EP2783686B1 (en) 2017-06-21
PT2269603E (pt) 2015-09-09
NO20033651D0 (no) 2003-08-18
IL229156A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
ES2629317T3 (es) Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina
US9549922B2 (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
ES2952265T3 (es) Terapia combinada que comprende un inhibidor de Raf y trametinib
KR20180132939A (ko) 암 치료를 위한 조합 요법
JP2012515184A (ja) 大腸がんの治療方法
JP2017516802A (ja) がんの治療におけるエリブリンの使用
US20210338686A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2015142867A1 (en) Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells
EP3151864A1 (en) Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
US20210308111A1 (en) Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers
ES2275619T3 (es) Quetiapina para el tratamiento de discinesia en pacientes no psicoticos.
AU2014279721A1 (en) Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
WO2019002542A1 (en) COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
US20220184034A1 (en) Methods for treating cutaneous metastatic cancers
WO2023009500A1 (en) Pentaaza macrocyclic ring complex for enhanced surgical treatment
KR20240004543A (ko) 혈액암을 치료하는 방법
WO2022043955A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
US20030139430A1 (en) Use of organic compounds
JP2023050198A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
EA040162B1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
KR20100131457A (ko) 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제